178 related articles for article (PubMed ID: 16776501)
1. Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling.
Lindsay KB; Skrydstrup T
J Org Chem; 2006 Jun; 71(13):4766-77. PubMed ID: 16776501
[TBL] [Abstract][Full Text] [Related]
2. Total synthesis of "aliskiren": the first Renin inhibitor in clinical practice for hypertension.
Hanessian S; Guesné S; Chénard E
Org Lett; 2010 Apr; 12(8):1816-9. PubMed ID: 20235519
[TBL] [Abstract][Full Text] [Related]
3. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
Maibaum J; Stutz S; Göschke R; Rigollier P; Yamaguchi Y; Cumin F; Rahuel J; Baum HP; Cohen NC; Schnell CR; Fuhrer W; Gruetter MG; Schilling W; Wood JM
J Med Chem; 2007 Oct; 50(20):4832-44. PubMed ID: 17824680
[TBL] [Abstract][Full Text] [Related]
4. The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.
Yamaguchi Y; Menear K; Cohen NC; Mah R; Cumin F; Schnell C; Wood JM; Maibaum J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4863-7. PubMed ID: 19615901
[TBL] [Abstract][Full Text] [Related]
5. Formal total synthesis of aliskiren.
Peters BK; Liu J; Margarita C; Andersson PG
Chemistry; 2015 May; 21(19):7292-6. PubMed ID: 25783891
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a hydroxyethylene isostere of the tripeptide Arg-Gly-Leu via a convergent acyl-like radical addition strategy.
Jensen CM; Lindsay KB; Andreasen P; Skrydstrup T
J Org Chem; 2005 Sep; 70(19):7512-9. PubMed ID: 16149778
[TBL] [Abstract][Full Text] [Related]
7. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
[TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of aliskiren, a potent renin inhibitor, using high-resolution nuclear magnetic resonance and molecular dynamics simulations.
Matsoukas MT; Zoumpoulakis P; Tselios T
J Chem Inf Model; 2011 Sep; 51(9):2386-97. PubMed ID: 21777001
[TBL] [Abstract][Full Text] [Related]
9. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren: a novel renin inhibitor for hypertension.
Tayal V; Kalra BS
Indian Heart J; 2008; 60(1):69-72. PubMed ID: 19212031
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge.
Cohen NC
Chem Biol Drug Des; 2007 Dec; 70(6):557-65. PubMed ID: 17999663
[TBL] [Abstract][Full Text] [Related]
12. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
13. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
14. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
15. Current concepts: renin inhibition in the treatment of hypertension.
Gradman AH; Pinto R; Kad R
Curr Opin Pharmacol; 2008 Apr; 8(2):120-6. PubMed ID: 18308634
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.
Wu Y; Shi C; Sun X; Wu X; Sun H
Bioorg Med Chem; 2011 Jul; 19(14):4238-49. PubMed ID: 21708467
[TBL] [Abstract][Full Text] [Related]
17. Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease.
Serebruany VL; Malinin A; Barsness G; Vahabi J; Atar D
J Hum Hypertens; 2008 May; 22(5):303-10. PubMed ID: 18273042
[TBL] [Abstract][Full Text] [Related]
18. Concise asymmetric total synthesis of scyphostatin, a potent inhibitor of neutral sphingomyelinase.
Fujioka H; Sawama Y; Kotoku N; Ohnaka T; Okitsu T; Murata N; Kubo O; Li R; Kita Y
Chemistry; 2007; 13(36):10225-38. PubMed ID: 17907134
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren, the future of renin-angiotensin system blockade?
Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren: clinical experience and future perspectives of renin inhibition.
Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
